PLEU17115 / AALL1621 / Mullen
Basic Study Information
Purpose:
This phase II trial studies how well inotuzumab ozogamicin works in treating younger
patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia
that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab
ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called
ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and
delivers ozogamicin to kill them.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Craig Mullen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search